Skip to main content

IBM CEO Ginni Rometty to step down

IBM Ginni Rometty will step down as chief of the technology giant.

IBM’s board of directors said on Thursday that they have elected Arvind Krishna to become the company’s new CEO on April 6, 2020. James Whitehurst, an IBM senior vice president and CEO of enterprise software firm Red Hat—which was acquired by IBM in July for $34 billion—will become IBM’s president in April.

Rometty will remain IBM’s chairman until the end of the year, when she will officially retire after a 40-year tenure at Big Blue.

“Arvind is the right CEO for the next era at IBM,” Rometty said in a statement. “He is a brilliant technologist who has played a significant role in developing our key technologies such as artificial intelligence, cloud, quantum computing and blockchain.”

Rometty’s plans to retire from IBM comes after years of declining revenue and a slumping share price, as the over-100-year-old company tried to retool itself amid a rapidly changing information technology market. Under her tenure, IBM experienced 22 consecutive quarters of sales declines that ended in 2017. In the company’s latest quarter, sales dropped 3.9% year-over-year to $18 billion.

When Rometty officially took over as IBM CEO in October 2012, IBM stock was at a split adjusted price of $161.72. Since then, IBM shares have dropped 15% to around $137. In after-hours trading on Thursday after IBM announced the upcoming executive change, its shares jumped 4.7% to $143.30, signaling that investors are pleased that Rometty will step down.

Rometty was IBM’s first female CEO and steered Big Blue during a time of massive disruption in the information technology market. The advent of cloud computing, in which companies like Amazon and Microsoft began selling computing resources on-demand, hurt IBM’s core businesses of selling software licenses, servers, and consulting services.

Some of Rometty’s biggest moves to help turn the company around included buying cloud computing company SoftLayer technologies for $2 billion, to bolster IBM’s cloud business and spending billions on its Watson data crunching technologies. But those big investments failed to significantly lift IBM’s sales, resulting in a slumping share price, with some analysts wishing its big bets would pay off sooner rather than later.

Patrick Moorhead, Principal Analyst at Moor Insights and Strategy, says it’s too early to judge Rometty’s tenure at IBM, explaining that it may take years for the company’s big investments to succeed. 

“I have to give them credit, it could have been a lot worse.” Moorhead says. “I know they didn’t grow financially, but people were saying they were dead.”

Moorhead likened IBM to other massive tech giants like the former Hewlett Packard and Dell Technologies, which all significantly upended their businesses to deal with the advent of cloud computing. For instance, Hewlett Packard split into data center specialist Hewlett Packard Enterprise and PC and printing giant HP, Inc. in 2015. Dell Technologies, meanwhile, bought data storage company EMC for $67 billion in 2016.

Moorhead notes the significance of Red Hat’s Whitehouse becoming IBM’s president, saying “I don’t recall in the history of IBM an outsider being that close to the top, ever.” But the decision to hand the CEO title to Krishna, who has worked at IBM for nearly 30 years, implies that IBM’s board was not looking for a “complete revamp” of IBM’s executive leadership.  

“Arvind has to execute the strategy flawlessly,” Moorehead says. “With Red Hat, there’s no going back.”

More must-read stories from Fortune:

—The long ocean voyage that helped find the flaws in GPS
—Global companies enter lockdown mode as coronavirus rocks China
—3 key takeaways from Tesla’s blockbuster fourth-quarter earnings
—Facebook says its ad machine is being weakened by privacy changes
—Predicting the biggest tech headlines of 2020

Catch up with Data Sheet, Fortune’s daily digest on the business of tech.



from Fortune https://ift.tt/3aYobZi
Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be
Post a Comment
Read more